Jim Robinson

Jim Robinson serves as the Chief Executive Officer of A2 Biotherapeutics, Inc. since April 2024, while also holding multiple board positions at Eledon Pharmaceuticals, Inc., Petauri, and UroGen Pharma starting in October 2023, and Urovant Sciences, Inc. from March 2020 to July 2023. Prior to A2 Biotherapeutics, Jim held key leadership roles at Paragon Biosciences, Alkermes, and Astellas Pharma, where significant contributions were made to operations and strategic direction, including responsibilities as President and Chief Operating Officer. Jim’s extensive experience in the biopharmaceutical sector began at Schering-Plough Pharmaceuticals, encompassing various sales and management positions. Educational qualifications include a degree from DePaul University.